The virus titer was determined by either plaque-forming assay (PFA) or focus-forming assay (FFA), depending on the ability of the virus to cause cytopathic effect (CPE). PFAs were performed for Paraiba_01/2015 and ZIKV ic, and FFAs were performed for GFP-50C/FrSh and nLuc-50C/FrSh. Briefly, WHO Vero cells were seeded in 24-well plates to reach 80–100% confluence on the day of the assay. Virus samples were ten-fold serially diluted in MEM supplemented with 1% FBS, and 100 µL of each dilution were used to infect the cells in duplicates. After 1 h incubation at 37 °C and 5% CO2 with periodic rocking of the plates, cells were overlaid with 0.8% methylcellulose in DMEM containing 2% FBS and 2 mM l-Glutamine and maintained at 37 °C and 5% CO2 for 4–5 days. Cells were fixed with cold methanol, and either stained with crystal violet for PFA or subjected to immunostaining using Anti-Flavivirus Group Antigen Antibody 4G2 (EMD Millipore, Burlington, MA, USA), goat anti-mouse HRP-conjugated secondary antibody (Jackson Immuno, West Grove, PA, USA) and True Blue peroxidase substrate (KPL, Silver Spring, MD, USA) for FFA.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.